Stock Analysis
Euronext Paris Growth Companies With High Insider Ownership And Up To 42% Revenue Growth
Reviewed by Simply Wall St
As political uncertainty and economic challenges continue to shape the landscape across European markets, France has not been immune to these pressures. In this context, identifying growth companies with high insider ownership on the Euronext Paris can offer investors potential resilience and alignment of interests between shareholders and management, especially in sectors demonstrating up to 42% revenue growth.
Top 10 Growth Companies With High Insider Ownership In France
| Name | Insider Ownership | Earnings Growth |
| VusionGroup (ENXTPA:VU) | 13.5% | 25.2% |
| Groupe OKwind Société anonyme (ENXTPA:ALOKW) | 24.8% | 30.6% |
| Adocia (ENXTPA:ADOC) | 12.1% | 104.5% |
| OSE Immunotherapeutics (ENXTPA:OSE) | 25.6% | 79.3% |
| Icape Holding (ENXTPA:ALICA) | 30.2% | 26.1% |
| Arcure (ENXTPA:ALCUR) | 21.4% | 42.4% |
| La Française de l'Energie (ENXTPA:FDE) | 20.1% | 34.2% |
| Munic (ENXTPA:ALMUN) | 29.4% | 150% |
| WALLIX GROUP (ENXTPA:ALLIX) | 19.8% | 101.6% |
| MedinCell (ENXTPA:MEDCL) | 16.4% | 74.6% |
Below we spotlight a couple of our favorites from our exclusive screener.
Lectra (ENXTPA:LSS)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Lectra SA offers industrial intelligence solutions across the fashion, automotive, and furniture sectors in various global regions including Northern Europe, Southern Europe, the Americas, and Asia Pacific, with a market capitalization of approximately €1.05 billion.
Operations: Lectra's revenue is primarily generated from the Americas and Asia-Pacific regions, with contributions of €170.33 million and €110.28 million respectively.
Insider Ownership: 19.6%
Revenue Growth Forecast: 11.3% p.a.
Lectra, a French company with substantial insider ownership, is trading at 35.7% below its estimated fair value, presenting an attractive entry point. Despite slower revenue growth forecasts of 11.3% compared to high-growth peers, earnings are expected to increase significantly by 28.6% annually over the next three years, outpacing the French market's average. Recent financials reveal a slight dip in net income and EPS in Q1 2024 but maintain steady sales growth year-over-year.
- Click here to discover the nuances of Lectra with our detailed analytical future growth report.
- Our comprehensive valuation report raises the possibility that Lectra is priced lower than what may be justified by its financials.
MedinCell (ENXTPA:MEDCL)
Simply Wall St Growth Rating: ★★★★★☆
Overview: MedinCell S.A. is a French pharmaceutical company specializing in the development of long-acting injectable medications across multiple therapeutic areas, with a market capitalization of approximately €393.48 million.
Operations: The company generates its revenue primarily from the pharmaceutical sector, totaling €11.95 million.
Insider Ownership: 16.4%
Revenue Growth Forecast: 42.9% p.a.
MedinCell, a French growth company with high insider ownership, is trading significantly below its fair value and is expected to become profitable within three years. Analysts predict a substantial rise in the stock price. Despite recent revenue declines and a net loss reported for FY 2024, MedinCell's revenue growth outpaces the French market significantly. The company's latest clinical trial showed promising results for its innovative drug delivery technology, although it didn't meet its primary endpoint.
- Get an in-depth perspective on MedinCell's performance by reading our analyst estimates report here.
- Our valuation report unveils the possibility MedinCell's shares may be trading at a discount.
OVH Groupe (ENXTPA:OVH)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: OVH Groupe S.A. operates globally, offering public and private cloud services, shared hosting, and dedicated server solutions with a market capitalization of approximately €0.99 billion.
Operations: The company generates revenue from three primary segments: Public Cloud (€140.71 million), Private Cloud (€514.59 million), and Web Cloud (€179.45 million).
Insider Ownership: 10.5%
Revenue Growth Forecast: 10.9% p.a.
OVH Groupe, a French growth company with high insider ownership, is expected to become profitable within the next three years, outpacing average market growth. Despite a highly volatile share price recently, its revenue growth at 10.9% annually is robust compared to the French market's 5.8%. Recent strategic hires like Celine Choussy and Benjamin Revcolevschi underscore its commitment to innovation and international expansion, although it currently faces a low forecasted return on equity of 3.7%.
- Unlock comprehensive insights into our analysis of OVH Groupe stock in this growth report.
- Our valuation report unveils the possibility OVH Groupe's shares may be trading at a premium.
Key Takeaways
- Navigate through the entire inventory of 22 Fast Growing Euronext Paris Companies With High Insider Ownership here.
- Got skin in the game with these stocks? Elevate how you manage them by using Simply Wall St's portfolio, where intuitive tools await to help optimize your investment outcomes.
- Invest smarter with the free Simply Wall St app providing detailed insights into every stock market around the globe.
Want To Explore Some Alternatives?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Valuation is complex, but we're helping make it simple.
Find out whether MedinCell is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About ENXTPA:MEDCL
MedinCell
A pharmaceutical company, develops long acting injectables in various therapeutic areas in France.
High growth potential and fair value.
